Dr. Arend on FDA Approval of Frontline Bevacizumab in Ovarian Cancer

Partner | Cancer Centers | <b>O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham</b>

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the FDA approval of bevacizumab (Avastin) as a frontline treatment in combination with carboplatin and paclitaxel, followed by bevacizumab alone, for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the FDA approval of bevacizumab (Avastin) as a frontline treatment in combination with carboplatin and paclitaxel, followed by bevacizumab alone, for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Related Content:

O’Neal Comprehensive Cancer Center at the University of Alabama at BirminghamOncLive TVOvarian Cancer
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL Management
Dr Moore on AEs Associated With ADC Treatment in Gynecologic Cancers